Optimized production of T cells expressing chimeric antigen receptors through PI3K inhibition with idelalisib

被引：0
|
作者：
Stock, S. [1 ]
Hoffmann, J. -M. [1 ]
Gern, U. [1 ]
Wang, L. [1 ]
Hueckelhoven, A. [1 ]
Neuber, B. [1 ]
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
Sellner, L. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V723
引用
收藏
页码：212 / 212
页数：1
相关论文
共 50 条
  • [31] Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
    Kawin Leelawat
    Siriluck Narong
    Wandee Udomchaiprasertkul
    Surang Leelawat
    Sumalee Tungpradubkul
    Cancer Cell International, 9
  • [32] Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
    Leelawat, Kawin
    Narong, Siriluck
    Udomchaiprasertkul, Wandee
    Leelawat, Surang
    Tungpradubkul, Sumalee
    CANCER CELL INTERNATIONAL, 2009, 9
  • [33] Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy
    Maryam Dadashi
    Atieh Pourbagheri-Sigaroodi
    Ali Anjam-Najmedini
    Davood Bashash
    Indian Journal of Hematology and Blood Transfusion, 2023, 39 : 208 - 219
  • [34] Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy
    Dadashi, Maryam
    Pourbagheri-Sigaroodi, Atieh
    Anjam-Najmedini, Ali
    Bashash, Davood
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2023, 39 (02) : 208 - 219
  • [35] Apicidin overcomes TRAIL-resistance on Bcr-AbI expressing K562 cells through inhibition of PI3K/AKT mediated pathway
    Park, S. J.
    Kim, M. J.
    Song, H. S.
    Kim, H. B.
    Kang, C. D.
    Kim, S. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 71 - 71
  • [36] Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma
    Okoli, Tracy C.
    Peer, Cody J.
    Dunleavy, Kieron
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2015, 16 (02) : 204 - 206
  • [37] DEVELOPMENT OF OPTIMIZED PROTOCOL FOR GENERATION OF NATURAL KILER CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS FROM HEMATOPOIETIC STEM CELLS FOR CANCER IMMUNOTHERAPY
    Patel, A.
    Truscott, L.
    De Oliveira, S. N.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (01) : 331 - 332
  • [38] Inhibition of VEGF blocks TGF-β1 production through a PI3K/Akt signalling pathway
    Lee, K. S.
    Park, S. J.
    Kim, S. R.
    Min, K. H.
    Lee, K. Y.
    Choe, Y. H.
    Hong, S. H.
    Lee, Y. R.
    Kim, J. S.
    Hong, S. J.
    Lee, Y. C.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (03) : 523 - 531
  • [39] Inhibition of wildtype PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust reactivation of wild-type PI3Kα signaling
    MacDougall, John R.
    Zhong, Mengqi
    Merritt, Hanne
    Del Cid, Joselyn S.
    Bradley, John
    Mak, Raymond
    Dhawan, Neil
    Chen, Wei
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kα inhibition through the transcriptional regulation of ERα
    Ding, Jinlei
    Wang, Xiaonan
    Zhang, Yuan
    Sang, Xiaolin
    Yi, Jingyan
    Liu, Chongya
    Liu, Zundong
    Wang, Min
    Zhang, Nan
    Xue, Yijue
    Shen, Lanlin
    Zhao, Wenzhi
    Luo, Fuwen
    Liu, Pixu
    Cheng, Hailing
    CANCER LETTERS, 2019, 440 : 54 - 63
12345